LAA Closure with AMULET and LAmbre Device

TCTAP 2023 7/5/2023 Sunday 7:00am to 8:00am Presentation Theater 1, Vista 3, B2

HKU Med

Simon Lam MBBS (HK) MRCP (UK) FRCP (Edin, Glas) FACC FESC Queen Mary Hospital, The University of Hong Kong

Disclosure

• Conflict of Interest – Nothing for Disclosure



AMULET



28th TCTAP

AbbottLeft Atrial AppendageAMULETOcclusion Device

Lobe

- Positioned **inside** the LAA neck
- Designed **to conform** to different sizes and shapes of LAA anatomy

Disc

• Designed to completely seal the LAA at the orifice

Stabilizing Wires


- Engage with the wall of the LAA
- Help hold the device in place

Waist

- Maintains tension between lobe and disc
- $\bullet \ {\bf Flexible \ connection} \ {\rm allows \ device \ to \ self-orient}$




Maximum Landing Zone Width (mm)	Amulet™D evice Size	Lobe Length (mm)	Minimum LAA Depth (mm)	Disc Diameter (mm)	Sheath Diameter
11.0-13.0	16	7.5	≥ 10	22	
13.0-15.0	18	7.5	≥ 10	24	12 F
15.0-17.0	20	7.5	≥ 10	26	or 14 F
17.0-19.0	22	7.5	≥ 10	28	(with adaptor)
19.0-22.0	25	10	≥ 12	32	
22.0-25.0	28	10	≥ 12	35	
25.0-28.0	31	10	≥ 12	38	14 F
28.0-31.0	34	10	≥ 12	41	




Device Size Selection - Amulet










WL: 128 WW: 256 [D] RAO: 30 CRA: 20

11/8/2016 15:20:40


PAT T: 37.0C TEE T: 39.7C

54 bpm

M4



CVRF






AMPLATZER ™ TorqVue™ 45°x 45° Delivery System



28th TCTAP




AMULET 25mm




28th TCTAP

CVRF






64bpm







28th TCTAP




60 bpm




AMULET 25mm















CVRF







o euro PCR

LAA Occlusion with the Amplatzer[™] Amulet[™] device: Primary results of the prospective global Amulet Observational Study


Dr. David Hildick-Smith, MD – Brighton and Sussex University Hospitals, Brighton, United Kingdom Prof. Ulf Landmesser, MD – Charité – University Medicine, Berlin, Germany
Prof. John Camm, MD – St. George's University Hospital, and Imperial College, London, United Kingdom Prof. Hans-Christoph Diener, MD, PhD – Universitätsklinikum Essen, Essen, Germany Dr. Vince Paul, MD – Fiona Stanley Hospital, Perth, Australia
Dr. Boris Schmidt, MD – Cardioangiologisches Centrum Bethanien, Frankfurt, Germany
Prof. Magnus Settergren, MD, PhD – Karolinska Universitetssjukhuset Solna, Stockholm, Sweden
Prof. Emmanual Teiger, MD, PhD – University Hospital Henri Mondor, Creteil, France
Prof. Jens Erik Nielsen-Kudsk, MD, DMSc – Aarhus University Hospital, Aarhus, Denmark
Prof. Claudio Tondo, MD, PhD – University of Milan, Milan, Italy
On Behalf of the Amulet Observational Study Investigators



PCRonline.com

and For you

Amulet IDE Trial





Information contained herein for PRESENTATION outside of the U.S. ONLY. Always check the regulatory status of the device in your region.

MAT-2211651 v1.0 | Item approved for OUS use only

CATALYST Study

				INVESTORS	NEWSROOM	RESPONSIBILITY	LIVE HEALTHY	
Abbott	CONSUMERS	HEALTHCARE PROFESSIONALS	CAREERS	ABOUT ABBOTT		s	EARCH	٩
HOME > NEWSROOM > PRESS	RELEASES							
		Contraction of the second						

O BACK TO PRESS RELEASES

ABBOTT ANNOUNCES FIRST-OF-ITS-KIND TRIAL TO ASSESS NEW THERAPY OPTION FOR PEOPLE AT RISK OF STROKE

- The CATALYST trial will examine Abbott's Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation



🖓 🖉 🖶

Photos (1)

ABBOTT PARK, Ill., Feb. 3, 2020 / PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved a new trial designed to assess its AmplatzerTM AmuletTM Left Atrial Appendage Occluder for people with atrial fibrillation (AF) - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a


LAmbre



28th TCTAP


Stable Device Fixation

Patented Anchor Design



Safely stabilized anchoring mechanism

- 8 small hooks (engage into LAA walls)
- 8 individual U-shaped ends (trapped in trabeculations)
- Over-sized umbrella (pushing and stenting against the LAA)




Fully Retrievable/Repositionable

Special design of the Umbrella


- Easily and fully retrievable/repositionable
- With less injury to LAA



Fully Retrievable/Repositionable



Device Sizes and Corresponding Delivery Systems of LAmbre







Cat.	Diameter of Umbrella(mm)	Diameter of Cover(mm)	Delivery system
LT-LAA-1622	16	22	8F-900 9F-900
LT-LAA-1824	18	24	10F-900
LT-LAA-2026	20	26	9F-900
LT-LAA-2228	22	28	10F-900
LT-LAA-2430	24	30	
LT-LAA-2632	26	32	
LT-LAA-2834	28	34	
LT-LAA-3036	30	36	107 000
LT-LAA-3236	32	36	10F-900
LT-LAA-3438	34	38	
LT-LAA-3640	36	40	

Cat.	Diameter of Umbrella(mm)	Diameter of Cover(mm)	Delivery system 9F-900 10F-900	
LT-LAA-1630	16	30		
LT-LAA-1832	18	32		
LT-LAA-2032	20	32		
LT-LAA-2234	22	34	10F-900	
LT-LAA-2436	24	36		
LT-LAA-2638	26	38		

LAA landing zone/ostium/depth measurement and Size Selection

Choose an Occluder 3-8mm larger than the measured landing zone;
 Selection of a Special-type Occluder (small umbrella with a relatively big cover) may be considered if the ostium is 10mm than landing zone;


LAmbre™ LAA Closure System

Delivery system

45° x 30°

Double


Curved



45° Single Curved








LAA closure


- ACIST injector Disable mode
- 2D and 3D TEE + Fluroscopic guidance
- 8.5Fr SL1 SJM Transseptal Sheath
- 89cm Baylis NRG Radiofrequency needle C1 curve (10W 2sec)
- ► 6Fr Pigtail
- 10 Fr Lambre 45 30 Delivery Sheath
- LAmbre #26 38mm
















PAT T: 37.0C TEE T: 39.4C







Case Illustration 2

Special LAA Morphology

- Small LAA
- LAA with multiple lobes and restrictive septum



Size: 16-36mm Cover 4-6mm larger





Size: 16-26mm Cover 12mm larger









CF 0,1305 mm/pix

12/4/2019 12:17:41 PM



Device Sizes and Corresponding Delivery Systems of LAmbre






Cat.	Diameter of Umbrella(mm)	Diameter of Cover(mm)	Delivery system	
LT-LAA-1622	16	22	8F-900 9F-900	
LT-LAA-1824	18	24	10F-900	
LT-LAA-2026	20	26	9F-900 10F-900	
LT-LAA-2228	22	28		
LT-LAA-2430	24	30		
LT-LAA-2632	26	32		
LT-LAA-2834	28	34	10F-900	
LT-LAA-3036	30	36		
LT-LAA-3236	32	36		
LT-LAA-3438	34	38		
LT-LAA-3640	36	40		



Cat.	Diameter of Umbrella(mm)	Diameter of Cover(mm)	Delivery system
LT-LAA-1630	16	30	9F-900 10F-900
LT-LAA-1832	18	32	
LT-LAA-2032	20	32	
LT-LAA-2234	22	34	10F-900
LT-LAA-2436	24	36	
LT-LAA-2638	26	38	




Queen Mary Hospital 0536-2019 XA Fluoroscopy




WL: 115 WW: 213 [D] RAO: 32 CAU: 17










0 135 180


Posterior lobule

Occluder in Anterior Iobule



Clinical Applications

Device deployment principles



Before releasing the cable, you must confirm the COST principle

China

LAmbre Study in China [1]

- ▶ 153 Patients, 12 Centers.
- Prospective, multicenter, open label, nonrandomized pilot trial
- Endpoint: safety, feasibility and efficacy of deploying LAmbre LAA occlusion device.
- Conclusion: LAA Closure with the LAmbre device shows encouraging results for stroke prevention in patients with NVAF.

Europe

LAmbre Study in Europe^[1]

- ▶ 60 Patients, 2 Centers in Germany.
- First European Experience with LAmbre.

Conclusion: Although minimizing procedure-related complications remains challenging, LAAO with the LAmbre showed high device success and good mid-term performance regarding prevention of stroke and bleeding.

Post-Market Clinical Follow-up

Lifetech LAmbreTM Left Atrial Appendage Closure System Post-Market Clinical Follow-up(LISA Study)

Study Design: Multi-center, single-arm, prospective, post-market study of LAmbre™ LAA Closure System

Principal Investigator: Prof.Horst Sievert, Hospital: Frankfurt CVC

Primary Objective: To evaluate immediate and long term procedural success of Lifetech LAmbre™ Occluders in patients.

Number of Subjects: 500 Patients

Post-Market Clinical Follow-up Total 26 centers; 13 centers from Germany;

PI	Site name	Country /Region
PD Dr. med. Kars Neven	Alfried Krupp Krankenhaus (Enrolment Completed)	Germany
PD Dr. med. Boris Schmidt	Cardioangiologisches Centrum Bethanien	Germany
Prof. Dr. med. Carsten Skurk	Charité Campus Benjamin Franklin	Germany
Dr. med. Alexander Sedaghat	Universitätsklinikum Bonn	Germany
PD Dr. med. Marcus Sandri	Herzzentrum Leipzig	Germany
Prof. Dr. med. Horst Sievert	CardioVasculäres Centrum	Germany
Prof. Dr. med. Thorsten Lewalter	Peter-Osypka-Herzzentrum	Germany
Dr. med. Ralph Stephan von Bardeleben	University Medical Center of Johannes Gutenberg-University Mainz	Germany
Dr. med. Anke Langbein	Praxisklinik Herz und Gefässe	Germany
Prof. Dr. med. Stefan G. Spitzer	Praxiskiinik Herz und Gerasse	
PD Dr. med. Sven Möbius-Winkler	Universitätsklinikum Jena	Germany
Dr. med. Norbert Klein	Klinikum St. Georg	Germany
Dr. med. Steffen Schnupp	Klinikum Coburg GmbH	Germany
PD Dr. Leif-Hendrik Boldt	Charité Campus Virchow Klinikum	Germany

Post-Market Clinical Follow-up

4 centers from Italy; 3 centers from Spain; Single center from Poland, Sweden, Hong Kong, Denmark, Ireland & Thailand.

PI	Site name	Country /Region
Prof. Achille Gaspardone	Ospedale S. Eugenio-ASL Roma 2	Italy
Dr. Jacopo Andrea Oreglia	ASST Grande Ospedale Metropolitano Niguarda	Italy
Prof. Claudio Tondo	Centro Cardiologico Fondazione Monzino	Italy
Clinica Mediterranea	Dr. Carlo Briguori	Italy
Prof. Ignacio Cruz Gonzalez	University Hospital Salamanca	Spain
Dr. Xavier Freixa Rofastes	Hospital Clínic de Barcelona	Spain
Dr. Beatriz Vaquerizo	FundacióInstitut Hospital del Mar d'Investigacions Mèdiques	Spain
Prof. Jan Z. Peruga	Bieganski Hospital	Poland
Prof. Dr. Jacob Odenstedt	Sahlgrenska University Hospital	Sweden
Dr. Simon Lam	Queen Marry Hospital	Hong Kong China
Prof. Dr. Jens Erik Nielsen Kudsk	Aarhus University Hospital	Denmark
Prof. Kevin Walsh	Mater Misericordiae University Hospital	Ireland
Ramathibodi Hospital	Dr. Mann Chandavimol	Thailand

Conclusion

- Device innovations and selections
- 2-Component Devices
 - AMULET
 - LAmbre
- Precautions and avoidance of potential complications
- Results and outcome optimization



